Financial Performance & Guidance - Q2 2025 total revenues reached $291 million, a 5% year-over-year increase[79] - The non-GAAP gross margin for Q2 2025 was 44.7%, a 50 bps increase[79] - Non-GAAP EBITDA for Q2 2025 was $38 million, a 4% decrease year-over-year[79] - Non-GAAP diluted earnings per share for Q2 2025 were $0.45, a $0.06 decrease[79] - The company projects total year 2025 revenue between $1.13 billion and $1.16 billion, a 3% year-over-year increase[80] - The company anticipates product bookings between $500 million and $550 million for 2025[86] - The company expects annual recurring revenue (ARR) between $610 million and $630 million for 2025[86] Strategic Focus & Growth - SaaS and Expert Services are targeted to reach 23% of total revenue in 2025[27] - The company has a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024[25] - The company is focused on expanding SaaS and Expert Services to capitalize on growth opportunities[29]

Financial Performance & Guidance - Q1 2025 total revenues reached $270 million, a 10% year-over-year increase[65] - Q1 2025 non-GAAP gross margin was 42.1%, a 230 basis points increase[65,82] - Q1 2025 non-GAAP EBITDA was $24 million, up 118% year-over-year[65,88] - The company projects 23% of total revenue for 2025 to come from SaaS and Expert Services[10,26] - The company anticipates total revenue between $1105 billion and $1155 billion for 2025[66,73] - The company expects annual recurring revenue between $610 million and $630 million for 2025[24,73] Strategic Focus - The company's product backlog stands at $647 million as of December 31, 2024[24] - The company is focused on SaaS and Expert Services to expand its Total Addressable Market (TAM)[24,27] - The company launched XT Amplify, Central Med Automation Service, and OmniSphere to focus on new products and services[10,55]